Key Highlights

  • Three Wall Street banks initiated coverage of Scribe Therapeutics with buy or outperform recommendations less than a month after its initial public offering
  • One bank's positive view centers on the company's differentiated epigenetic silencing approach for lowering cardiovascular disease risk without permanent genetic modification
  • The stock has surged more than 44% since its Nasdaq debut in late July, outperforming the broader market
  • Analysts say the company holds an advantage as the only public company with an epigenetic silencer currently in clinical development

Banks Turn Bullish Following IPO Debut

Wall Street analysts are confident that Scribe Therapeutics (NASDAQ:SCTX) can continue its rally after going public less than a month ago, with three separate banks initiating coverage of the gene-editing company this week. One bank assigned an overweight recommendation to the stock, citing a differentiated PCSK9 epigenetic silencing approach that could potentially offer years-long durability without permanent genetic modification. The bank pointed to first-in-human data expected in the first half of 2027 as a key value-driving catalyst.

A second bank gave the stock an outperform recommendation, while a third assigned a buy rating, both citing the company's gene-editing platform and pipeline potential. Founded in 2018, Scribe Therapeutics aims to use gene-editing technology to modify or remove DNA sequences in human cells with the goal of lowering risk for cardiovascular and other diseases, and specializes in leveraging epigenetic silencing, the process of turning off genes, for therapeutic purposes.

Stock Has Outperformed Since Nasdaq Debut

The company went public on the Nasdaq in late July, with its stock debuting at $15 per share, the higher end of its expected range. Since its initial public offering, Scribe Therapeutics has surged more than 44%, vastly outperforming the broader market.

One of the banks noted that the stock is likely to gain further ground by leveraging two proprietary systems for gene editing, both based on a naturally occurring enzyme that makes editing genes relatively easier and more predictable compared with other approaches. The bank added that Scribe also holds an advantage as the only public company with an epigenetic silencer currently in clinical development, giving it a competitive edge over rivals in the development of gene-focused therapeutics.